219 related articles for article (PubMed ID: 23934050)
41. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
42. [Biosimilars in the European Union: current situation and challenges].
Wolff-Holz E; Weise M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
[TBL] [Abstract][Full Text] [Related]
43. Biological agents and biosimilars: Essential information for the internist.
Pasina L; Casadei G; Nobili A
Eur J Intern Med; 2016 Sep; 33():28-35. PubMed ID: 27342030
[TBL] [Abstract][Full Text] [Related]
44. Fractal geometry as a new approach for proving nanosimilarity: a reflection note.
Demetzos C; Pippa N
Int J Pharm; 2015 Apr; 483(1-2):1-5. PubMed ID: 25659328
[TBL] [Abstract][Full Text] [Related]
45. Biosimilars: current scientific and regulatory considerations.
Chugh PK; Roy V
Curr Clin Pharmacol; 2014 Feb; 9(1):53-63. PubMed ID: 23952143
[TBL] [Abstract][Full Text] [Related]
46. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
47. Biosimilars - terms of use.
Declerck P; Mellstedt H; Danese S
Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731
[TBL] [Abstract][Full Text] [Related]
48. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
49. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
50. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
51. Some thoughts on drug interchangeability.
Chow SC; Song F; Chen M
J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
[TBL] [Abstract][Full Text] [Related]
52. Biosimilars: the need, the challenge, the future: the FDA perspective.
Epstein MS; Ehrenpreis ED; Kulkarni PM;
Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
[TBL] [Abstract][Full Text] [Related]
53. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
Scheinberg M; Castañeda-Hernández G
Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
[TBL] [Abstract][Full Text] [Related]
54. An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins.
Heinemann L; Khatami H; McKinnon R; Home P
Diabetes Technol Ther; 2015 Jul; 17(7):510-26. PubMed ID: 25789689
[TBL] [Abstract][Full Text] [Related]
55. Biosimilars in IBD: from theory to practice.
Danese S; Bonovas S; Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):22-31. PubMed ID: 27729659
[TBL] [Abstract][Full Text] [Related]
56. Similar or the Same? Why Biosimilars are not the Solution.
Diependaele L; Cockbain J; Sterckx S
J Law Med Ethics; 2018 Sep; 46(3):776-790. PubMed ID: 30336096
[TBL] [Abstract][Full Text] [Related]
57. Biosimilar therapeutics-what do we need to consider?
Schellekens H
NDT Plus; 2009 Jan; 2(Suppl_1):i27-i36. PubMed ID: 19461855
[TBL] [Abstract][Full Text] [Related]
58. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
59. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
60. Biosimilars: controversies as illustrated by rhGH.
Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
